First subjects screened in Aptahem’s FIH study with Apta-1
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that the first healthy volunteers have been screened for inclusion in the clinical First in Human (FIH) study with the drug candidate Apta-1.
The randomized, placebo-controlled Phase 1 study will evaluate the safety and tolerability of intravenous Apta-1 in healthy volunteers (HV). The first HV subjects have now been screened and are ready for the first dosing later in December.
CEO Mikael Lindstam comments:
”It is with great pleasure that we have received the news that the first healthy volunteers now have been screened for inclusion in our FIH study. This marks an important step for the company and we are all very excited to follow the progress of this study.”
For further information:
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com
Forward-looking statements
This press release contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, similar to research and development work in the biotech field, associated with risk and uncertainty. In light of this, actual outcomes may differ substantially from what is described in this press release.
About Aptahem
Aptahem AB (APTA) is a clinical stage biotechnology company that develops aptamer-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company’s lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com